An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Zymeworks Announces Participation in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical firm, announced its participation in two key investor conferences. On April 12, the company will hold one-on-one meetings at the Wells Fargo 2022 Biotech Forum in Palm Beach Gardens, FL. Additionally, Zymeworks will present and participate in meetings on May 2 at Bloom Burton & Co. Healthcare Investor Conference at 2:00 p.m. ET. These events will be webcast live, providing further engagement opportunities for investors.
Positive
None.
Negative
None.
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences:
Wells Fargo 2022 Biotech Forum. Zymeworks will participate in one-on-one meetings on April 12th in Palm Beach Gardens, FL.
Bloom Burton & Co.Healthcare Investor Conference. Zymeworks will participate in one-on-one meetings and will present on May 2nd at 2:00 p.m. ET.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.
What investor conferences is Zymeworks participating in April 2022?
Zymeworks will participate in the Wells Fargo 2022 Biotech Forum on April 12 for one-on-one meetings in Palm Beach Gardens, FL.
When is Zymeworks presenting at the Bloom Burton & Co. Healthcare Investor Conference?
Zymeworks will present on May 2, 2022, at 2:00 p.m. ET during the Bloom Burton & Co. Healthcare Investor Conference.
Where can I watch the Zymeworks conference presentations?
The presentations will be webcast live and available for replay on Zymeworks' website.
What are the main clinical candidates being developed by Zymeworks?
Zymeworks' lead candidate, zanidatamab, targets HER2 and is in multiple clinical trials. Their second candidate, ZW49, is also a HER2-targeted drug currently in Phase 1 development.
